{"id":"m923","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"M923 works by binding to and modifying the glycan structures on the Fc region of IgG antibodies, which enhances their ability to engage Fc receptors on immune cells. This glycoengineering approach aims to improve the effector functions of endogenous IgG antibodies, potentially enhancing immune responses against disease targets. The mechanism leverages Momenta's expertise in glycoprotein engineering to optimize antibody-mediated immunity.","oneSentence":"M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:58.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune and inflammatory diseases (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT02675023","phase":"PHASE1","title":"Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Healthy","enrollment":603},{"nctId":"NCT02581345","phase":"PHASE3","title":"Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Chronic Plaque Psoriasis, Psoriasis","enrollment":572},{"nctId":"NCT02722044","phase":"PHASE3","title":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab"],"phase":"phase_3","status":"active","brandName":"M923","genericName":"M923","companyName":"Momenta Pharmaceuticals, Inc.","companyId":"momenta-pharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"M923 is a monoclonal antibody that targets and modulates IgG glycosylation to enhance immune function. Used for Autoimmune and inflammatory diseases (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}